Geron (GERN) Receivables - Other (2010 - 2026)
Geron (GERN) posted Receivables - Other of $2.2 million for Q1 2026, down 1.16% sequentially from $2.2 million in Q4 2025, and down 21.44% YoY from $2.8 million in Q1 2025.
Geron (GERN) Receivables - Other (2010 - 2026) Analysis & Trends
Geron has reported Receivables - Other for 17 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Receivables - Other fell 21.44% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 21.44% YoY) and the FY2025 annual result came in at $2.2 million, down 21.52% from the prior year.
- Receivables - Other fell to $2.2 million in Q1 2026 per GERN's latest filing, from $2.2 million in the prior quarter.
- Over five years, Receivables - Other peaked at $22.2 million in Q3 2022 and troughed at $1.6 million in Q1 2024.
- A 5-year average of $4.7 million and a median of $2.8 million in 2025 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2022 and 2024: Receivables - Other jumped 3543.11% in 2022, then sank 80.49% in 2024.
- Over 5 years, Receivables - Other stood at $3.1 million in 2022, then slumped by 47.36% to $1.7 million in 2023, then surged by 72.39% to $2.9 million in 2024, then declined by 21.52% to $2.2 million in 2025, then slipped by 1.16% to $2.2 million in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $2.2 million, $2.2 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Mn |
| Jun 30, 2026 | 1.86 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | 2.82 Mn |
| Mar 31, 2025 | 2.82 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.63 Mn |